{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:29:12Z","timestamp":1790008152125,"version":"4.0.1"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>The arrival of new medications for Alzheimer disease (AD) has prompted efforts to measure their value using conventional cost-effectiveness analyses; however, these analyses focus on how much health improvement new medications generate per dollar spent. As AD disproportionately affects older adults, women, racial and ethnic minority individuals, and individuals with lower socioeconomic and educational levels, it is critical to also examine the health equity outcomes of treatment.<\/jats:p><\/jats:sec>Objective<\/jats:title>To estimate the health equity impact of a hypothetical disease-modifying treatment for early AD in the US and to examine targeted policies to mitigate health care disparities.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This economic evaluation, which used a distributional cost-effectiveness analysis, was conducted from June 16, 2022, to January 11, 2024. The study included subgroups defined by race and ethnicity and by social vulnerability quintiles in the US.<\/jats:p><\/jats:sec>Exposures<\/jats:title>A hypothetical disease-modifying treatment compared with best supportive care.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The main outcomes were population-level quality-adjusted life-years (QALYs), lifetime costs, and net health benefits. The social welfare impact and change in health inequality were estimated using the Atkinson index.<\/jats:p><\/jats:sec>Results<\/jats:title>The distributional cost-effectiveness analysis simulated 316\u202f037\u202f100 individuals from the US population, including 25 subgroups defined by 5 categories of race and ethnicity and population quintiles of social vulnerability, with the fifth quintile representing the most socially vulnerable group. At an opportunity cost benchmark of $150\u202f000 per QALY, treatment was associated with improved population health, adding 28\u202f197 QALYs per year to the US population. Accounting for health inequality preferences (using an aversion level of 11, based on an Atkinson inequality aversion parameter\u2009that can range from 0 to infinity, with higher values assigning greater weight to health gains that accrue to the population with the lowest lifetime quality-adjusted life expectancy), treatment was associated with a 0.009% reduction in existing population health inequalities annually. Scenario analyses examining earlier and expanded treatment access suggested a population health improvement of up to 221\u202f358 QALYs.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The findings of this economic evaluation suggest that treatment for AD could improve population health and health equity. Policies to enable earlier diagnosis and treatment initiation, as well as expanded access to treatment, may further improve treatment and health equity impacts.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.42353","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T15:33:05Z","timestamp":1730388785000},"page":"e2442353","source":"Crossref","is-referenced-by-count":11,"title":["Modeling the Population Equity of Alzheimer Disease Treatments in the US"],"prefix":"10.1001","volume":"7","author":[{"given":"Patricia G.","family":"Synnott","sequence":"first","affiliation":[{"name":"Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Majda","sequence":"additional","affiliation":[{"name":"Evidence for Access, Public Affairs and Access, Genentech, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Jung","family":"Lin","sequence":"additional","affiliation":[{"name":"Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Ollendorf","sequence":"additional","affiliation":[{"name":"Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Zhu","sequence":"additional","affiliation":[{"name":"Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Kowal","sequence":"additional","affiliation":[{"name":"Evidence for Access, Public Affairs and Access, Genentech, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,10,31]]},"reference":[{"issue":"3","key":"zoi241218r1","first-page":"872","article-title":"Health disparities in dementia.","volume":"28","author":"Balls-Berry","year":"2022","journal-title":"Continuum (Minneap Minn)"},{"issue":"4","key":"zoi241218r2","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/alz.13016","article-title":"2023 Alzheimer\u2019s disease facts and figures.","volume":"19","year":"2023","journal-title":"Alzheimers Dement"},{"key":"zoi241218r3","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.trci.2019.11.008","article-title":"Racial disparities and temporal trends in dementia misdiagnosis risk in the United States.","volume":"5","author":"Gianattasio","year":"2019","journal-title":"Alzheimers Dement (N Y)"},{"issue":"8","key":"zoi241218r4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1097\/MLR.0000000000001577","article-title":"Dementia diagnosis disparities by race and ethnicity.","volume":"59","author":"Lin","year":"2021","journal-title":"Med Care"},{"issue":"8","key":"zoi241218r5","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/alz.12509","article-title":"Black and White individuals differ in dementia prevalence, risk factors, and symptomatic presentation.","volume":"18","author":"Lennon","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"1","key":"zoi241218r6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13195-023-01272-z","article-title":"Expected and diagnosed rates of mild cognitive impairment and dementia in the U.S. Medicare population: observational analysis.","volume":"15","author":"Mattke","year":"2023","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"zoi241218r9","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/jamaneurol.2022.0315","article-title":"Cost-effectiveness of aducanumab and donanemab for early Alzheimer disease in the US.","volume":"79","author":"Ross","year":"2022","journal-title":"JAMA Neurol"},{"issue":"1","key":"zoi241218r10","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12256","article-title":"Cost-effectiveness of aducanumab to prevent Alzheimer\u2019s disease progression at current list price.","volume":"8","author":"Sinha","year":"2022","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"zoi241218r11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1177\/0272989X15583266","article-title":"Distributional cost-effectiveness analysis: a tutorial.","volume":"36","author":"Asaria","year":"2016","journal-title":"Med Decis Making"},{"issue":"12","key":"zoi241218r13","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1001\/jamaneurol.2022.3543","article-title":"Estimating the prevalence of dementia and mild cognitive impairment in the US: the 2016 Health and Retirement Study Harmonized Cognitive Assessment Protocol project.","volume":"79","author":"Manly","year":"2022","journal-title":"JAMA Neurol"},{"issue":"4","key":"zoi241218r14","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jalz.2008.03.001","article-title":"Diagnosis and assessment of Alzheimer\u2019s disease in diverse populations.","volume":"4","author":"Dilworth-Anderson","year":"2008","journal-title":"Alzheimers Dement"},{"issue":"6","key":"zoi241218r15","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S1047-2797(02)00437-4","article-title":"Prevalence of dementia in three ethnic groups: the South Florida Program on Aging and Health.","volume":"13","author":"Demirovic","year":"2003","journal-title":"Ann Epidemiol"},{"issue":"1","key":"zoi241218r16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3233\/JAD-150778","article-title":"A meta-analysis of Alzheimer\u2019s disease incidence and prevalence comparing African-Americans and Caucasians.","volume":"50","author":"Steenland","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"zoi241218r17","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamaneurol.2020.4471","article-title":"Trends in relative incidence and prevalence of dementia across non-Hispanic Black and White individuals in the United States, 2000-2016.","volume":"78","author":"Power","year":"2021","journal-title":"JAMA Neurol"},{"issue":"10","key":"zoi241218r20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.29392","article-title":"Evaluation of the cost-effectiveness of drug treatment for Alzheimer disease in a simulation model that includes caregiver and societal factors.","volume":"4","author":"Ito","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"6","key":"zoi241218r21","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial.","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"zoi241218r23","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12385","article-title":"Alzheimer\u2019s disease drug development pipeline: 2023.","volume":"9","author":"Cummings","year":"2023","journal-title":"Alzheimers Dement (N Y)"},{"key":"zoi241218r24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.lana.2021.100179","article-title":"Racial\/ethnic disparities in length of life after dementia diagnosis: an 18-year follow-up study of Medicare beneficiaries.","volume":"8","author":"Chen","year":"2022","journal-title":"Lancet Reg Health Am"},{"issue":"5","key":"zoi241218r25","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1002\/alz.12822","article-title":"Estimating prevalence of early Alzheimer\u2019s disease in the United States, accounting for racial and ethnic diversity.","volume":"19","author":"Gillis","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"10","key":"zoi241218r27","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.jval.2023.06.015","article-title":"Estimating the US baseline distribution of health inequalities across race, ethnicity, and geography for equity-informative cost-effectiveness analysis.","volume":"26","author":"Kowal","year":"2023","journal-title":"Value Health"},{"issue":"1","key":"zoi241218r29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7326\/M20-1392","article-title":"A health opportunity cost threshold for cost-effectiveness analysis in the United States.","volume":"174","author":"Vanness","year":"2021","journal-title":"Ann Intern Med"},{"issue":"3","key":"zoi241218r30","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/0022-0531(70)90039-6","article-title":"On the measurement of inequality.","volume":"2","author":"Atkinson","year":"1970","journal-title":"J Econ Theory"},{"issue":"10","key":"zoi241218r31","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/hec.3430","article-title":"Eliciting the level of health inequality aversion in England.","volume":"26","author":"Robson","year":"2017","journal-title":"Health Econ"},{"issue":"8","key":"zoi241218r32","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s40273-023-01281-8","article-title":"Distributional cost-effectiveness analysis of treatments for non-small cell lung cancer: an illustration of an aggregate analysis and its key drivers.","volume":"41","author":"Meunier","year":"2023","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"zoi241218r33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation.","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol"},{"issue":"6","key":"zoi241218r34","doi-asserted-by":"publisher","first-page":"779","DOI":"10.7326\/M22-3272","article-title":"Distributional cost-effectiveness of equity-enhancing gene therapy in sickle cell disease in the United States.","volume":"176","author":"Goshua","year":"2023","journal-title":"Ann Intern Med"},{"issue":"2","key":"zoi241218r35","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jval.2022.08.010","article-title":"The impact of funding inpatient treatments for COVID-19 on health equity in the United States: a distributional cost-effectiveness analysis.","volume":"26","author":"Kowal","year":"2023","journal-title":"Value Health"},{"issue":"9","key":"zoi241218r36","doi-asserted-by":"publisher","first-page":"e581","DOI":"10.1016\/S2352-3018(21)00147-8","article-title":"Improving health equity and ending the HIV epidemic in the USA: a distributional cost-effectiveness analysis in six cities.","volume":"8","author":"Quan","year":"2021","journal-title":"Lancet HIV"},{"issue":"12","key":"zoi241218r37","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/j.jval.2023.08.010","article-title":"The health inequality impact of liquid biopsy to inform first-line treatment of advanced non-small cell lung cancer: a distributional cost-effectiveness analysis.","volume":"26","author":"Jansen","year":"2023","journal-title":"Value Health"},{"issue":"2","key":"zoi241218r38","doi-asserted-by":"publisher","first-page":"138","DOI":"10.2307\/2137221","article-title":"Ethnic differences in caregiving duties and burdens among parents and siblings of persons with severe mental illnesses.","volume":"36","author":"Horwitz","year":"1995","journal-title":"J Health Soc Behav"},{"issue":"5","key":"zoi241218r39","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1093\/geront\/gnaa028","article-title":"Systematic review and meta-analysis of racial and ethnic differences in dementia caregivers\u2019 well-being.","volume":"61","author":"Liu","year":"2021","journal-title":"Gerontologist"},{"issue":"16","key":"zoi241218r40","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1001\/jama.287.16.2090","article-title":"Patient and caregiver characteristics and nursing home placement in patients with dementia.","volume":"287","author":"Yaffe","year":"2002","journal-title":"JAMA"},{"key":"zoi241218r12","doi-asserted-by":"crossref","DOI":"10.1093\/med\/9780198838197.001.0001","volume-title":"Distributional Cost-Effectiveness Analysis: Quantifying Health Equity Impacts and Trade-Offs","author":"Cookson","year":"2020"},{"key":"zoi241218r7","unstructured":"Lin? GA, Whittington? MD, Synnott? PG, ; Institute for Clinical and Economic Review for the California Technology Assessment Forum. Aducanumab for Alzheimer\u2019s disease: effectiveness and value. Final evidence report and meeting summary. August 5, 2021. Accessed May 25, 2023. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_ALZ_Final_Report_080521.pdf"},{"key":"zoi241218r8","unstructured":"Lin? GA, Whittington? MD, Wright? A, ; Institute for Clinical and Economic Review for the California Technology Assessment Forum. Lecanemab for early Alzheimer\u2019s disease. Final evidence report. April 17, 2023. Accessed May 25, 2023. https:\/\/icer.org\/wp-content\/uploads\/2023\/04\/ICER_Alzheimers-Disease_Final-Report_For-Publication_04172023.pdf"},{"key":"zoi241218r18","unstructured":"2016 American Community Survey (ACS) state and county dashboard. US Census Bureau. December 7, 2017. Accessed October 14, 2022. https:\/\/www.census.gov\/library\/visualizations\/interactive\/acs-5year-datamap.html"},{"key":"zoi241218r19","unstructured":"CDC\/ATSDR SVI 2020 documentation. Centers for Disease Control and Prevention. August 5, 2022. Accessed May 20, 2023. https:\/\/www.atsdr.cdc.gov\/placeandhealth\/svi\/documentation\/pdf\/SVI2020Documentation_08.05.22.pdf"},{"key":"zoi241218r22","unstructured":"Kulic? L, Alcaraz? F, Vogt? A, . Roche. The anti-amyloid beta Brainshuttle\u2122 antibody Trontinemab rapidly reduces amyloid plaques in participants with Alzheimer\u2019s disease. October 25, 2023. Accessed February 29, 2024. https:\/\/medically.roche.com\/content\/dam\/pdmahub\/restricted\/neurology\/ctad-2023\/CTAD-2023-presentation-kulic-the-anti-amyloid-beta.pdf"},{"key":"zoi241218r26","unstructured":"Johnson? RW. Office of the Assistant Secretary for Planning and Evaluation; US Department of Health and Human Services. What is the lifetime risk of needing and receiving long-term services and supports? April 3, 2019. Accessed January 26, 2024. https:\/\/aspe.hhs.gov\/reports\/what-lifetime-risk-needing-receiving-long-term-services-supports-0"},{"key":"zoi241218r28","unstructured":"Mapping Medicare disparities by population. Centers for Medicare & Medicaid Services. Updated June 26, 2024. Accessed September 24, 2024. https:\/\/data.cms.gov\/tools\/mapping-medicare-disparities-by-population"},{"key":"zoi241218r41","unstructured":"Ollendorf? DA, Cookson? R, Kowal? S, Synnott? P, Onukwugha? E. We need better data, not just new drugs, to reduce disparities in Alzheimer\u2019s care. Health Affairs. November 17, 2023. Accessed January 26, 2024. https:\/\/www.healthaffairs.org\/content\/forefront\/we-need-better-data-not-just-new-drugs-reduce-disparities-alzheimer-s-care"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2825511\/synnott_2024_oi_241218_1733416456.58812.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T16:41:58Z","timestamp":1733848918000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2825511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,31]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.42353","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,31]]}}}